Activated CD4 T Cells and Highly Differentiated Alloreactive CD4 T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients
Overview
General Surgery
Authors
Affiliations
Spontaneous operational tolerance to the allograft develops in a proportion of liver transplantation (LT) recipients weaned off immunosuppressive (IS) drugs. Several studies have investigated whether peripheral blood circulating T cells could play a role in the development or identify operational tolerance, but never characterized alloreactive T cells in detail due to the lack of a marker for these T cells. In this study, we comprehensively investigated phenotypic and functional characteristics of alloreactive circulating T cell subsets in tolerant LT recipients (n = 15) using multiparameter flow cytometry and compared these with LT recipients on IS drugs (n = 23) and healthy individuals (n = 16). Activation-induced CD137 was used as a marker for alloreactive T cells upon allogenic stimulation. We found that central and effector memory CD4+ T cells were hyporesponsive against donor and third-party splenocyte stimulation in tolerant LT recipients, whereas an overall hyperresponsiveness was observed in alloreactive terminally differentiated effector memory CD4+ T cells. In addition, elevated percentages of circulating activated T helper cells were observed in these recipients. Lastly, tolerant and control LT recipients did not differ in donor-specific antibody formation. In conclusion, a combination of circulating hyperresponsive highly differentiated alloreactive CD4+ T cells and circulating activated T helper cells could discriminate tolerant recipients from a larger group of LT recipients.
Betjes M, De Weerd A Front Med (Lausanne). 2023; 10:1215167.
PMID: 37502354 PMC: 10368955. DOI: 10.3389/fmed.2023.1215167.
Litjens N, van der List A, Klepper M, Prevoo F, Boer K, Hesselink D Clin Exp Immunol. 2023; 213(3):371-383.
PMID: 37070703 PMC: 10571010. DOI: 10.1093/cei/uxad041.
Duizendstra A, van der Grift M, Boor P, Noordam L, de Knegt R, Peppelenbosch M Front Immunol. 2022; 12:738837.
PMID: 35087511 PMC: 8787265. DOI: 10.3389/fimmu.2021.738837.